158 related articles for article (PubMed ID: 37623491)
1. Effectiveness of Dupilumab in the Treatment of Adult and Older Adult Patients with Severe, Uncontrolled CRSwNP.
Ottaviano G; De Corso E; Saccardo T; D'Auria LM; Zampollo S; D'Agostino G; Mairani E; De Maio G; Scarpa B; Bacci C; Favero V
J Pers Med; 2023 Aug; 13(8):. PubMed ID: 37623491
[TBL] [Abstract][Full Text] [Related]
2. Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab.
Ottaviano G; De Corso E; Cantone E; Ciofalo A; Saccardo T; Bernardi R; Mairani E; Montuori C; Roccuzzo G; Soldati L; Randon B; Zampollo S; Chicco AD; Visconti F; Scarpa B; Nicolai P
J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836468
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Dupilumab in the Treatment of Patients with Uncontrolled Severe CRSwNP: A "Real-Life" Observational Study in Naïve and Post-Surgical Patients.
Ottaviano G; Saccardo T; Roccuzzo G; Bernardi R; Chicco AD; Pendolino AL; Scarpa B; Mairani E; Nicolai P
J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143311
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
Galletti C; Ragusa M; Sireci F; Ciodaro F; Barbieri MA; Giunta G; Grigaliute E; Immordino A; Lorusso F; Dispenza F; Freni F; Galletti F; Gallina S; La Mantia I; Galletti B
Am J Otolaryngol; 2024; 45(1):104106. PubMed ID: 37948824
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
6. Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP Patients.
Alicandri-Ciufelli M; Marchioni D; Pipolo C; Garzaro M; Nitro L; Dell'Era V; Ferrella F; Campagnoli M; Russo P; Galloni C; Ghidini A; De Corso E; Lucidi D
Laryngoscope; 2024 Apr; 134(4):1556-1563. PubMed ID: 37632705
[TBL] [Abstract][Full Text] [Related]
7. Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP.
Cantone E; De Corso E; Ricciardiello F; Di Nola C; Grimaldi G; Allocca V; Motta G
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 35893310
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dupilumab in real-life settings: a STROBE study.
Gal A; Gravier-Dumonceau R; Penicaud M; Ebode D; Radulesco T; Michel J
Eur Arch Otorhinolaryngol; 2024 Mar; ():. PubMed ID: 38498194
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Dupilumab on Work Productivity and Emotional Health in CRSwNP: A Multicentric Study in Northeast Italy.
Ottaviano G; Roccuzzo G; Lora L; Bison E; Tosin E; Calvanese L; Cestaro W; Locatello LG; Corlianò F; Stellin M; Baldovin M; Trimarchi MV; Bertocco AG; Maculan M; Scarpa B; Saccardo T; Nicolai P
J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793051
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab (Dupixent
Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
13. Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience.
Bellocchi G; Loperfido A; Passali FM; Millarelli S; Velletrani G; Perla M; Di Michele L; Di Girolamo S
Acta Biomed; 2023 Oct; 94(5):e2023227. PubMed ID: 37850768
[TBL] [Abstract][Full Text] [Related]
14. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
Scangas GA; Wu AW; Ting JY; Metson R; Walgama E; Shrime MG; Higgins TS
Laryngoscope; 2021 Jan; 131(1):E26-E33. PubMed ID: 32243622
[TBL] [Abstract][Full Text] [Related]
15. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
Dharmarajan H; Falade O; Lee SE; Wang EW
Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature.
Reale M; Licci G; Orlando P; Matucci A; Trabalzini F; Maggiore G; Gallo O
Eur Arch Otorhinolaryngol; 2024 May; ():. PubMed ID: 38762844
[TBL] [Abstract][Full Text] [Related]
20. Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up.
Kiricsi A; Bella Z; Kraxner H; Szaloki T; Fent Z; Liktor B; Huszka J; Laszlo P; Gobol D; Helfferich F; Vaska Z; Piski Z; Juhasz-Loisch L; Horvath B; Galantai G; Krisztin N; Toth L; Bodi A; Matuz M; Lujber L; Hirschberg A
Rhinology; 2024 Jun; ():. PubMed ID: 38848046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
